Table 1.
Effect of SGLT2 inhibitors on clinical outcomes in adults with diabetic kidney disease
| Outcome | No. studies | No. events | Sample size | HR (95% CI) | I2, % | PHeterogeneity | PEgger test |
|---|---|---|---|---|---|---|---|
| MACE | 6 | 2271 | 21,913 | 0.83 (0.75–0.93) | 33.8 | 0.183 | 0.287 |
| Kidney composite | 5 | 1197 | 21,195 | 0.66 (0.58–0.75) | 0.0 | 0.949 | 0.513 |
| HHF | 6 | 1219 | 22,346 | 0.62 (0.55–0.71) | 0.0 | 0.844 | 0.267 |
| Cardiovascular death | 5 | 953 | 20,539 | 0.84 (0.74–0.96) | 0.0 | 0.639 | 0.996 |
| Fatal and nonfatal MI | 5 | 498* | 20,108 | 0.78 (0.67–0.92) | 7.7 | 0.363 | 0.671 |
| Fatal and nonfatal stroke | 5 | 332* | 20,108 | 0.76 (0.59–0.97) | 41.3 | 0.146 | 0.564 |
| All-cause mortality | 5 | 1451 | 21,406 | 0.86 (0.77–0.96) | 14.5 | 0.322 | 0.268 |
*The number of MI events and stroke cases from the SCORED trial were not reported in the primary trials and are not included in the table. CI indicates confidence interval; HHF hospitalization for heart failure, HR hazard ratio, I2, I-squared, MACE Major Adverse Cardiovascular Events, MI myocardial infarction, SCORED Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk, SGLT2 sodium-glucose cotransporter 2; SGLT2, sodium-glucose cotransporter 2, SOLOIST-WHF Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure, VERTIS CV Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial